We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real‐world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2‐year experience.
- Authors
Fujiwara, Chisako; Uchiyama, Akihiko; Inoue, Yuta; Ishikawa, Mai; Motegi, Sei‐ichiro
- Abstract
Objective: Dupilumab has been deemed highly effective for atopic dermatitis (AD). However, there have been no reports performing a combination analysis with hematological data and improvement rates pertaining to the continued use of dupilumab for up to 2 years in real world. In this study, we evaluated the effectiveness and safety of using dupilumab for up to 2 years in 9 patients with AD at our hospital. Methods: Thirty‐six patients with moderate‐to‐severe AD treated by dupilumab, and 9 of them treated for 2 years. Changes in the severity scoring, pruritus numerical rating scale (NRS), patient‐oriented eczema measure (POEM), serum levels of immunoglobulin E (IgE), thymus and activation‐regulated chemokine (TARC), eosinophils, and lactate dehydrogenase (LDH) at Week 0, 2, 4, 16, 48, 72, and 96 of those patients were investigated, and we studied features of the patients who had any adverse events (AEs). Results: Investigator's global assessment (IGA), eczema area and severity index (EASI), body surface area (BSA), NRS, POEM, and serum levels of LDH were significantly decreased from Week 4 onwards to Week 96 compared with baseline condition. Serum levels of TARC and LDH were significantly decreased from Week 4 onwards to Week 96. Regarding 9 patients who were treated with dupilumab for up to 2 years, serum levels of TARC and eosinophils decreased without statistical significance. The serum levels of IgE significantly decreased at Week 72, 96 compared with the baseline. Regarding as AEs, ocular symptoms were the most frequently observed (15/36, 41.2%), and there were no cases of discontinuation due to AEs. Conclusions: Treatment with dupilumab was well tolerated and showed improvements in AD for at least 2 years. In this study, we performed a combination analysis with hematological data and improvement rates for up to 2 years in 9 patients with AD using dupilumab at our hospital. The effect was sustained in cases treated for a period of 2 years. Severe AEs were not observed.
- Subjects
ATOPIC dermatitis; IMMUNOGLOBULIN E; PATIENT safety; BODY surface area; DUPILUMAB; ECZEMA
- Publication
Journal of Cutaneous Immunology & Allergy, 2023, Vol 6, Issue 3, p88
- ISSN
2574-4593
- Publication type
Article
- DOI
10.1002/cia2.12280